PMVP earnings analysis
What we found in PMVP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not include the income statement, cash-flow statement, balance sheet detail, or segment disclosures needed to assess quarterly revenue, margins, EPS, operating cash flow, or free cash flow. The filing reports $79.4 million of cash, cash equivalents, and marketable securities as of June 30, 2026, but introduces a high-severity going-concern disclosure stating that current resources may not fund planned operations for at least one year. No quantitative revenue or EPS guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $79.4M in cash and securities
- Cash, cash equivalents, and marketable securities totaled $79.4 million as of June 30, 2026. Management stated that interest-rate exposure was not material because of the nature and amount of the company’s money-market funds and marketable securities.
- Controls remained effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, with no material changes in internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern uncertainty
- The company disclosed substantial doubt about its ability to continue as a going concern. Management stated that present capital resources may not be sufficient to fund planned operations for at least one year from the August 14, 2026 report date, creating dependence on additional financing.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q. The filing instead states that present capital resources may not be sufficient to fund planned operations for at least one year from the report date.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 12, 2026
- PMV Pharmaceuticals reported a net loss of $18 million for Q1 2026, worsening slightly from a loss of $17.4 million in Q1 2025. The company continues to invest heavily in the rezatapopt clinical program, with $15.33…
- 10-K · March 6, 2026
- PMV Pharmaceuticals continues to pursue clinical development in the competitive biotechnology market with a focus on the lead product candidate rezatapopt. Despite incurring significant net losses and reporting zero…
- 10-Q · November 12, 2025
- PMV Pharmaceuticals reported a net loss of $21.1 million for Q3 2025, consistent with previous quarters of negative performance, resulting in diluted EPS of -$0.4. Total cash and cash equivalents decreased to $36.3…
- 10-Q · August 7, 2025
- PMV Pharmaceuticals, Inc. reported a continued negative performance in Q2 2025, with an operating loss of $22.9 million and a net loss of $21.2 million. The company's revenue remains at $0, reflecting ongoing challenges…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PMVP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever